Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia
Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia
The anti-CD20 monoclonal antibody rituximab (MabThera®/Rituxan®) has been proven to improve outcomes in a range of B-cell malignancies. Initially developed as a formulation for intravenous infusion, administration times for rituximab can be prolonged and associated with infusion-related reactions, prompting a combined clinical development program investigating subcutaneous delivery in combination with recombinant human hyaluronidase. As this program comes to fruition, this article reviews the evidence demonstrating subcutaneous rituximab to have noninferior pharmacokinetics when delivered at a fixed-dose as well as equivalent clinical outcomes in the treatment of follicular lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma. This mode of delivery is more preferable to patients and healthcare professionals and is associated with time and cost savings.
Journal Article
1691-1699
Hill, Samuel Luke
72d727e6-0e71-4e35-8dc3-7123650800b5
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
June 2018
Hill, Samuel Luke
72d727e6-0e71-4e35-8dc3-7123650800b5
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Hill, Samuel Luke and Davies, Andrew
(2018)
Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Future Oncology, 14 (17), .
(doi:10.2217/fon-2017-0574).
Abstract
The anti-CD20 monoclonal antibody rituximab (MabThera®/Rituxan®) has been proven to improve outcomes in a range of B-cell malignancies. Initially developed as a formulation for intravenous infusion, administration times for rituximab can be prolonged and associated with infusion-related reactions, prompting a combined clinical development program investigating subcutaneous delivery in combination with recombinant human hyaluronidase. As this program comes to fruition, this article reviews the evidence demonstrating subcutaneous rituximab to have noninferior pharmacokinetics when delivered at a fixed-dose as well as equivalent clinical outcomes in the treatment of follicular lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma. This mode of delivery is more preferable to patients and healthcare professionals and is associated with time and cost savings.
Text
Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia
- Accepted Manuscript
More information
e-pub ahead of print date: 6 February 2018
Published date: June 2018
Keywords:
Journal Article
Identifiers
Local EPrints ID: 417913
URI: http://eprints.soton.ac.uk/id/eprint/417913
ISSN: 1479-6694
PURE UUID: 4408ad0b-6024-4d2a-b8a5-1ef2b4fa36b3
Catalogue record
Date deposited: 16 Feb 2018 17:30
Last modified: 16 Mar 2024 06:12
Export record
Altmetrics
Contributors
Author:
Samuel Luke Hill
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
